Literature DB >> 9095204

Time to systemic metastases in patients with posterior uveal melanoma.

T Sato1, A Babazono, J A Shields, C L Shields, P De Potter, M J Mastrangelo.   

Abstract

A total of 116 patients, all of whom had systemic metastases from posterior uveal melanoma, were evaluated to identify potential indicators for time to systemic metastasis. In the multivariate Cox proportional hazards model with clinically available variables, the age at initial treatment for uveal melanoma, gender and diameter of the primary tumor were revealed to be independent predictive factors for time to systemic metastasis. Age older than 60 years, male gender, and diameter of the primary uveal melanoma more than 10 mm were proved to be independent unfavorable factors. The estimated median time to systemic metastasis for the most unfavorable group (age > 60, male, diameter > 10 mm) was 20.2 months in contrast with 76.1 months for the most favorable group (age < or = 60, female, diameter < or = 10 mm). Although the results of this study cannot be applied to all patients with posterior uveal melanoma, predictive factors for time to systemic metastasis in those patients who have recurred supplement the information obtained from prognostic factors for the likelihood of metastasis or survival. They contribute not only to our understanding of the biology of metastasizing posterior uveal melanoma, but also in developing appropriate strategies for follow-up and treatment.

Entities:  

Mesh:

Year:  1997        PMID: 9095204     DOI: 10.3109/07357909709115761

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  7 in total

1.  High-dose immunoembolization: survival benefit in patients with hepatic metastases from uveal melanoma.

Authors:  Akira Yamamoto; Inna Chervoneva; Kevin L Sullivan; David J Eschelman; Carin F Gonsalves; Michael J Mastrangelo; David Berd; Jerry A Shields; Carol L Shields; Mizue Terai; Takami Sato
Journal:  Radiology       Date:  2009-07       Impact factor: 11.105

2.  Recruiting donors for autopsy based cancer research.

Authors:  J Thombs; N J Borthwick; J L Hungerford; I A Cree
Journal:  J Med Ethics       Date:  2005-06       Impact factor: 2.903

3.  Post-menopausal bleeding: a rare presentation of metastatic uveal melanoma.

Authors:  Michael A Coutts; Nicola J Borthwick; John L Hungerford; Ian A Cree
Journal:  Pathol Oncol Res       Date:  2006-09-23       Impact factor: 3.201

4.  [Safety and efficacy of interferon alfa-2b in the adjuvant treatment of uveal melanoma].

Authors:  E Richtig; G Langmann; G Schlemmer; K Müllner; G Papaefthymiou; P Bergthaler; J Smolle
Journal:  Ophthalmologe       Date:  2006-06       Impact factor: 1.059

5.  Multinodular goiter and primary hyperparathyroidism: a circuitous route to diagnosing metastatic uveal melanoma.

Authors:  Constantine G A Theoharis; Tobias Carling; Natalia Buza; Eduardo Zambrano; Julie Ann Sosa
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

6.  Long-term survival in a patient with unresectable liver metastases from uveal melanoma treated with transarterial chemoembolization with irinotecan eluting beads - case report and review of literature.

Authors:  Katarzyna Stanisławska; Honorata Stadnik; Mikołaj Nawrocki; Katarzyna Ramlau-Piątek; Robert Juszkat; Michał Drews
Journal:  Contemp Oncol (Pozn)       Date:  2017-09-29

7.  An Outcome Assessment of a Single Institution's Longitudinal Experience with Uveal Melanoma Patients with Liver Metastasis.

Authors:  Rino S Seedor; David J Eschelman; Carin F Gonsalves; Robert D Adamo; Marlana Orloff; Anjum Amjad; Erin Sharpe-Mills; Inna Chervoneva; Carol L Shields; Jerry A Shields; Michael J Mastrangelo; Takami Sato
Journal:  Cancers (Basel)       Date:  2020-01-01       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.